TheEdgeResearch
Home / Stocks / AURA

Aura Biosciences, Inc. (AURA)

NASDAQ Healthcare Biotechnology
$6.87 ▼ -1.58%
Market Cap
$715.0M
Sector
Healthcare
Industry
Biotechnology
Beta
0.44
52-Wk Range
4.73-9.54
CEO
Natalie C. Holles
Country
US
Currency
USD

Aura Biosciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $6.87, down 1.58% on the session, giving a market capitalisation of $715.0M. On trailing twelve-month figures it carries a trailing P/E of -4.11, a net margin of 0.0%. Its beta of 0.44 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-4.11
Price / Sales
0.00
Price / Book
2.65
EV / EBITDA
-4.88
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.06
Current ratio
14.21
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
113
IPO date
2021-10-29
Headquarters
Boston, MA, US
About Aura Biosciences, Inc.

Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.

Comparable companies

Aura Biosciences, Inc. is most often compared with the following Healthcare names:

AKTSBCYCCRBPEYPTIMNMMGNXOCGNOCSOTLKWHWK
More research on AURA
AURA technical analysis AURA TheEdge Score Compare against peers
Open full interactive analysis & DCF →